#United States #Chicago #Ractigen Therapeutics #RAG-17 #SOD1-ALS

Ractigen Therapeutics Presents Promising Phase I Data for RAG-17 in SOD1-ALS

At the recent 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago, Ractigen Therapeutics showcased favorable preliminary findings from their Phase I/II clinical trial investigating RAG-17. This novel small interfering RNA (siRNA) therapeutic is specifically aimed at treating patients with amyotrophic lateral sclerosis (ALS) linked to mutations in the SOD1 gene. The presentation was led by Dr. Zhi-Ying Wu, highlighting Ractigen's commitment to advancing RNA-based therapies.

Key Findings from the Phase I Trial

The Phase I trial, which involved a single ascending dose (SAD) strategy, aimed to evaluate the safety and efficacy of RAG-17 among 20 participants across five sequential doses (30, 90, 120, 150, and 180 mg). The most striking outcome was an impressive 81.2% decrease in plasma neurofilament light chain (NfL) levels in the 180 mg cohort, demonstrating a robust biomarker change indicative of neurodegeneration.

Safety and Tolerability

Safety data revealed that RAG-17 was well-tolerated across all dosing groups. Notably, there were no serious adverse events reported, which signifies the potential of RAG-17 as a safe treatment option. Only mild, treatment-related adverse events were observed, further underpinning the encouraging safety profile of this therapy.

Clinical Stabilization Signals

In addition to biomarker improvements, some participants showed signs of clinical stabilization as per the ALS Functional Rating Score-Revised (ALSFRS-R). In particular, three patients in the 180 mg group exhibited no functional decline at Day 90 post-dosing, an early but encouraging signal for ongoing clinical efficacy.

Innovative Delivery Mechanism

RAG-17 employs Ractigen's proprietary Smart Chemistry-Aided Delivery (SCAD™) technology, which facilitates extensive distribution within the central nervous system from a single intrathecal injection. This innovative mechanism aims not only to achieve significant therapeutic effects but also to extend dosing intervals compared to existing ALS treatments.

Dr. Long-Cheng Li, CEO of Ractigen, expressed optimism about the findings, stating, "Achieving an 81% reduction in plasma NfL—a critical marker of neuroaxonal damage—alongside an excellent safety profile from a single administration is groundbreaking. We are excited to have commenced dosing in the Phase II segment of the study to explore RAG-17's potential further."

Launching into Phase II Trials

Currently, Ractigen Therapeutics is moving forward with a Phase II clinical trial, which is a randomized, double-blind, placebo-controlled study involving multiple ascending doses of RAG-17. The trial is crucial in assessing the drug's long-term safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients diagnosed with SOD1 mutations. Enrollment for initial cohorts has already been successfully completed.

Looking Ahead

The journey of RAG-17 is a hopeful beacon for patients battling SOD1-ALS, a condition that has greatly limited treatment options despite its clear genetic marker. As the trial progresses, Ractigen aims to solidify its findings and expand its therapeutic arsenal against this devastating condition. The company continues to highlight its innovative RNA therapies, believing they will significantly impact the landscape of treatments for challenging medical conditions.

In the face of such promising results, the medical community is eager to witness the outcomes of Ractigen's Phase II trials. For more details about Ractigen Therapeutics and their groundbreaking work, visit their website at www.ractigen.com.